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ABSTRACT
The relentless emergence and spread of antimicrobial resistance warrant an increased awareness of the
problem and improved coordination and standardisation of surveillance systems, as well as resistance
control strategies. Moreover, this underscores the urgent need for new antibiotics active against the
emerging resistant pathogens. Ceftobiprole is a new b-lactam molecule engineered for bactericidal
activity against methicillin-resistant staphylococci that also exhibits an extended broad spectrum of
activity covering the most clinically important Gram-positive (methicillin-susceptible staphylococci,
penicillin-susceptible and -resistant pneumococci, other streptococci and ampicillin-susceptible entero-
cocci) and Gram-negative (Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp., Haemophilus
spp. and Moraxella spp.) pathogens. Results from studies with experimental infections and from clinical
trials support a role for ceftobiprole in treating complicated skin and skin structure infections caused by
Gram-positive pathogens, including methicillin-resistant staphylococci, and suggest a potential role for
this drug in treating other types of serious infection caused by Gram-positive and Gram-negative
pathogens.
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THE INCREASING PROBLEM OF
ANTIMICROBIAL RESISTANCE
Resistance to antibiotics has become a problem of
global dimensions, and resistance trends are, over-
all, on the increase. The impact of antibiotic
resistance on morbidity, mortality and healthcare
costs has been clearly demonstrated for several
resistant pathogens, including methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resist-
ant enterococci and multidrug-resistant Gram-
negative bacilli [1]. Several such examples are
presented and discussed in detail by Goldstein [2].
MRSA remains one of the most important
resistance issues at the beginning of the 21st
century, due to the worldwide diffusion and
magnitude of the problem. In several nosocomial
settings, the prevalence of MRSA outnumbers
that of methicillin-susceptible S. aureus, and the
recent spread of MRSA in the community [3],
which is related both to the carriage of nosocomial
MRSA strains from the hospital into the commu-
nity, and to the direct emergence of new commu-
nity-associated (CA) MRSA strains due to
selective pressure generated by the use of antibi-
otics in community medicine, has remarkable
implications for the selection of empirical therapy
to treat community-acquired staphylococcal infec-
tions. The spread of CA-MRSA has already been
shown to have a considerable impact in the USA
[4], while in Europe and elsewhere, the actual
impact of CA-MRSA remains to be clarified [5].
Despite several efforts to control resistance in
general and MRSA dissemination in particular
that are underway at the institutional level, MRSA
and other resistant pathogens are likely to remain
a major problem in the years to come, and the
development of new antibiotics active against
MRSA and other multidrug-resistant bacteria
remains a high priority in drug discovery and
development programmes.
RESISTANCE SURVEILLANCE:
IMPORTANCE AND PITFALLS
In a world where antibiotic resistance is globally
widespread but heterogeneously distributed and
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rapidly evolving, surveillance is a matter of
paramount importance. It is vital to monitor the
general evolution of the phenomenon of resist-
ance, but also to obtain epidemiological informa-
tion at the local level, because updated
knowledge on resistance epidemiology is essen-
tial to customise guidelines for empirical antimi-
crobial therapy.
Several large-scale surveillance systems have
been implemented that provide information on
the epidemiology and trends of the most import-
ant resistant pathogens on an international or
even intercontinental scale [5]. However, surveil-
lance systems are not exempt from potential
biases and shortcomings. Major problems influ-
encing the quality and appropriate application of
surveillance data can include: (i) diversity of data
collection methods and sampling criteria; (ii)
unbalanced representation of collected data; (iii)
lack of adequate patient denominators; and (iv)
variability in the susceptibility testing procedures
and interpretive criteria adopted by different
surveillance systems [5]. To address these prob-
lems, better coordination and standardisation
among different surveillance systems are essential
for improving the overall utility of the data and
for facilitating comparison of the results provided
by different systems.
Analysis and presentation of surveillance data
are also important issues. While data are most
often presented in the form of prevalence of
resistant isolates, information on the incidence of
infections caused by resistance pathogens, which
may not directly reflect the raw prevalence data,
is also meaningful because it would allow us to
assess more precisely the public health impact of
the phenomenon.
The available surveillance data currently indi-
cate an overall global dissemination of MRSA
resistance, although with remarkably different
impacts in different countries and also in different
regions of the same country. In the USA, the
prevalence of MRSA is currently higher than 50%
among isolates from hospitalised patients and
higher than 40% among those from outpatients
[6], and the dissemination of CA-MRSA is well
established [4]. In Europe, the reported preval-
ence of MRSA and the incidence of MRSA
bacteraemias can vary greatly among countries
(European Antimicrobial Resistance Surveillance
System; available at: http://www.rivm.nl/earss),
suggesting a dynamic situation in which the
epidemiology of CA-MRSA remains to be clar-
ified [5].
Significant variability in MRSA rates can also
be observed according to the type of hospital and
hospital ward surveyed; MRSA rates are known
to be generally higher in intensive care and
nephrology units than in other hospital wards,
and are also higher in large teaching hospitals
(which accept transferred patients) than in smal-
ler district general hospitals [5]. Among patient-
specific factors, an age-dependent relationship is
apparent in MRSA rates, with the elderly popu-
lation showing a greater risk of MRSA colonisa-
tion and infection; this is likely to be related to a
higher rate of hospitalisation and contact with the
healthcare system among the elderly population,
and to their residence in nursing homes [5].
Assessment of other risk-factors for MRSA infec-
tions can be important to assess the need for anti-
MRSA coverage in initial empirical therapeutic
regimens.
CEFTOBIPROLE: A NEW EXPANDED-
SPECTRUM b-LACTAM ENGINEERED
FOR ANTI-MRSA ACTIVITY
Ceftobiprole is a new cephalosporin engineered to
bind strongly to penicillin-binding protein (PBP) 2¢
(2a) of MRSA and of methicillin-resistant coagu-
lase-negative staphylococci (MR-CoNS) and there-
by inhibit its activity [7]. The potent in-vitro
activity of ceftobiprole has been recently docu-
mented in large collections of isolates of MRSA
(including some vancomycin intermediately resist-
ant S. aureus and vancomycin-resistant S. aureus
strains) and MR-CoNS, with MIC90 values gener-
ally of 2 mg ⁄L and MIC ranges of £0.25–4 and
£0.015–8 mg ⁄L for MRSA and MR-CoNS, respect-
ively [8]. The activity of ceftobiprole is bactericidal,
with killing kinetics that are faster than those
observed with glycopeptides against MRSA and
methicillin-susceptible staphylococci [8].
In addition to its anti-staphylococcal activity,
ceftobiprole is active against pneumococci (includ-
ing penicillin-intermediate and penicillin-resistant
strains, for which ceftobiprole activity is superior to
that of other cephalosporins) and ampicillin-sus-
ceptible enterococci, although it is not active
against ampicillin-resistant enterococci producing
the low-affinity PBP5. Unlike most of the new non-
b-lactam antimicrobial agents with anti-MRSA
activity, which are essentially narrow-spectrum
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drugs targeting Gram-positive pathogens (e.g.,
linezolid, daptomycin, dalbavancin and telavan-
cin), ceftobiprole has a spectrum of activity that
also covers several clinically important Gram-
negative pathogens, including Haemophilus influ-
enzae, Moraxella catarrhalis, Enterobacteriaceae,
Pseudomonas aeruginosa and Acinetobacter bauman-
nii. The good activity of ceftobiprole against these
Gram-negative pathogens is related to the good
stability of ceftobiprole in the presence of broad-
spectrum b-lactamases of functional group 2b and,
to a lesser extent, AmpC-like b-lactamases. Like
other cephalosporins, ceftobiprole is not stable in
the presence of the extended-spectrum b-lactamas-
es, serine-carbapenemases, and metallo-b-lacta-
mases, and production of these enzymes can be
responsible for acquired resistance to this drug
among Enterobacteriaceae and non-fastidious
Gram-negative non-fermenters. Ceftobiprole is
also not stable in the presence of the chromosomal
b-lactamases of Proteus vulgaris, Bacteroides fragilis,
and other Bacteroides spp., which appear to be
naturally resistant. Ceftobiprole exhibits relatively
good activity against some clostridia, while other
Gram-positive and Gram-negative anaerobes are
less susceptible or resistant [8].
Compared with the several cephalosporins
available for clinical use, the antibacterial spec-
trum of ceftobiprole most closely resembles
that of cefepime, although ceftobiprole demon-
strates unique activity against MRSA and MR-
CoNS and superior activity against enterococci
and Acinetobacter. Ceftobiprole can thus be clearly
differentiated from other cephalosporins as a new
anti-MRSA expanded-spectrum cephalosporin.
In-vivo data obtained with animal models
showed good activity of ceftobiprole in several
types of experimental infection, including mouse
septicaemia, subcutaneous abscesses and pneu-
monia, rabbit osteomyelitis, and rat or rabbit
endocarditis caused by susceptible isolates of
Gram-positive and Gram-negative species [8].
The human pharmacokinetic profile of ceftobi-
prole (administered as the prodrug ceftobiprole-
medocaril, which is rapidly converted to the active
drug by plasma esterases) reveals a major distri-
bution in the extracellular space and primary
excretion, unchanged, through urine. Ceftobiprole
has a half-life of approximately 3 h and a dose-
proportional AUC and Cmax over a broad dose
range (125–1000 mg), with low intra- and inter-
subject variability [7]. A dosing regimen of 750 mg
every 12 h was used in the phase II study, and
regimens of 500 mg every 8 or 12 h have been used
in the phase III clinical studies, because recent
pharmacokinetic and pharmacodynamic data sug-
gest that 500 mg every 8 h infused intravenously
over 2 h is the preferred regimen for maximal
activity in Gram-negative and Gram-positive infec-
tions and has an acceptable safety ⁄ tolerability
profile [7].
In phase II studies in patients with complicated
skin and skin structure infections (cSSSIs) mostly
caused by Gram-positive pathogens, including a
number of MRSA strains, ceftobiprole showed
good clinical efficacy, including against all MRSA
infections [7]. Preliminary results from a phase III
clinical study on cSSSIs caused by Gram-positive
pathogens, including MRSA, in which ceftobipro-
le (500 mg every 12 h) was compared to vanco-
mycin (1000 mg every 12 h), revealed overall
similar clinical cure rates (93%). These studies
confirm the safety and tolerability of ceftobiprole
that were anticipated from the results of phase I
and II studies [7].
Available and emerging data endorse the clin-
ical value of ceftobiprole for the treatment of
cSSSIs (including those caused by MRSA), and
suggest that ceftobiprole could also be useful in
treating other infections caused by Gram-positive
and Gram-negative pathogens.
CONCLUSION
Ours is an era characterised by globally increasing
and rapidly evolving antibiotic resistance in all
major bacterial pathogens, together with a serious
shortage in the pipeline of new antibiotics for
resistant pathogens. It is vitally important to
increase the awareness of the problem of resist-
ance, to enhance the coordination and standard-
isation of resistance surveillance systems, to
improve the efficacy of resistance control strat-
egies, and to encourage research into and devel-
opment of new antibiotics with activity against
emerging resistant pathogens.
Ceftobiprole is a new parenteral b-lactam with
bactericidal activity against methicillin-resistant
staphylococci, and is the first cephalosporin to
demonstrate clinical efficacy in the treatment of
infections caused by methicillin-resistant staphy-
lococci. Unlike most other non-b-lactam anti-
MRSA agents, ceftobiprole exhibits an extended
broad-spectrum activity against the most clinically
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important Gram-positive and Gram-negative path-
ogens. As such, ceftobiprole clearly represents a
significant advance in the field of antimicrobial
chemotherapy. It will be of value to continue large-
scale surveillance programmes to monitor micro-
biological activity and evolution of resistance,
particularly for resistant pathogens (e.g., vanco-
mycin-resistant enterococci and extended-spec-
trum b-lactamase-producing Enterobacteriaceae)
that are known to be selected by some other classes
of expanded-spectrum cephalosporin. Building on
previous reports of the potent in-vitro and in-vivo
activity of ceftobiprole, results from phase III
studies on cSSSIs caused by Gram-positive patho-
gens demonstrate its excellent activity against all
infections, including those caused by MRSA. Fur-
ther clinical investigations to assess the value of
ceftobiprole for treating other types of serious
infection caused by Gram-positive and Gram-
negative pathogens are ongoing.
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